Rxsight Inc (RXST) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Rxsight Inc (RXST) has a cash flow conversion efficiency ratio of -0.041x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.89 Million) by net assets ($267.30 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See RXST defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Rxsight Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Rxsight Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Rxsight Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rxsight Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BIDV Insurance Corp
VN:BIC
|
-0.050x |
|
Legal & General Group PLC
LSE:LGEN
|
2.275x |
|
Astec LifeSciences Limited
NSE:ASTEC
|
-0.020x |
|
Circio Holding ASA
OL:CRNA
|
2.054x |
|
Amotech Co. Ltd
KQ:052710
|
0.021x |
|
PTT Synergy Group Bhd
KLSE:7010
|
-0.233x |
|
Thanulux Public Company Limited
BK:TNL
|
-0.039x |
|
Amway (Malaysia) Holdings Bhd
KLSE:6351
|
0.283x |
Annual Cash Flow Conversion Efficiency for Rxsight Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Rxsight Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Rxsight Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $275.68 Million | $-15.51 Million | -0.056x | +6.62% |
| 2024-12-31 | $281.24 Million | $-16.95 Million | -0.060x | +76.77% |
| 2023-12-31 | $160.36 Million | $-41.59 Million | -0.259x | +60.38% |
| 2022-12-31 | $89.90 Million | $-58.85 Million | -0.655x | -102.41% |
| 2021-12-31 | $138.24 Million | $-44.71 Million | -0.323x | -373.33% |
| 2020-12-31 | $-297.53 Million | $-35.20 Million | 0.118x | -11.27% |
| 2019-12-31 | $-304.61 Million | $-40.62 Million | 0.133x | -- |
About Rxsight Inc
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adju… Read more